AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
197.01
-1.01 (-0.51%)
As of 9:44AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close198.02
Open196.30
Bid195.59 x 1000
Ask198.01 x 900
Day's Range195.65 - 197.88
52 Week Range163.31 - 210.19
Volume160,951
Avg. Volume2,526,158
Market Cap127.519B
Beta (3Y Monthly)1.53
PE Ratio (TTM)59.02
EPS (TTM)3.34
Earnings DateOct 30, 2018
Forward Dividend & Yield5.28 (2.67%)
Ex-Dividend Date2018-08-16
1y Target Est205.15
Trade prices are not sourced from all markets
  • Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates
    Zacks18 hours ago

    Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates

    Novartis (NVS) beats sales estimates in Q3, driven by Cosentyx and Entresto, while earnings came in line. The company plans to acquire Endocyte to broaden its oncology pipeline.

  • Better Buy: Biogen Inc. vs. Amgen Inc.
    Motley Fool2 days ago

    Better Buy: Biogen Inc. vs. Amgen Inc.

    Which of these giant biotech stocks is the better pick right now?

  • 3 Dividend Stocks for Income
    Motley Fool3 days ago

    3 Dividend Stocks for Income

    It's hard to find high-quality dividend stocks worth adding to portfolios, but these companies could be the exception.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
    Zacks4 days ago

    Amgen (AMGN) Dips More Than Broader Markets: What You Should Know

    Amgen (AMGN) closed the most recent trading day at $201.80, moving -0.45% from the previous trading session.

  • Biogen: Revenue Growth Is Expected in Q3
    Market Realist4 days ago

    Biogen: Revenue Growth Is Expected in Q3

    As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.

  • Investopedia4 days ago

    Biotech Sector Could Enter Bear Market

    Biotech price action at all capitalization levels has deteriorated in recent weeks, with the two major sector funds giving up the majority of their 2018 gains. The iShares Nasdaq Biotechnology Index Fund ( IBB) and the SPDR S&P Biotech ETF ( XBI) carve different price patterns due to their unique holdings and construction. The market-cap weighted Nasdaq fund is dependent upon its biggest components, with Amgen Inc. ( AMGN), Gilead Sciences, Inc. ( GILD), Biogen Inc. ( BGEN) and Celgene Corporation ( CELG) comprising more than 32% of portfolio weighting.

  • Analyzing Biogen before Its Third-Quarter Earnings
    Market Realist4 days ago

    Analyzing Biogen before Its Third-Quarter Earnings

    Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.

  • AMGN or ILMN: Which Is the Better Value Stock Right Now?
    Zacks4 days ago

    AMGN or ILMN: Which Is the Better Value Stock Right Now?

    AMGN vs. ILMN: Which Stock Is the Better Value Option?

  • 10 S&P 500 Stocks to Buy for the Long Term
    Kiplinger4 days ago

    10 S&P 500 Stocks to Buy for the Long Term

    The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance

  • GlobeNewswire4 days ago

    Investor Expectations to Drive Momentum within Amgen, Crown Castle International, Constellation Brands, Nice, NetEase, and The Hanover Insurance Group — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realist5 days ago

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.

  • PR Newswire5 days ago

    Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies

    THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores (nano-scale holes made by proteins contained within a synthetic membrane) in combination with electronics to perform direct, real-time sequencing of DNA and RNA. The investment in Oxford Nanopore aligns with Amgen's strategic focus on using human genetics to deliver new medicines to patients.

  • Financial Times5 days ago

    [$$] Amgen invests £50m in gene-reading company Oxford Nanopore

    , the US biotechnology group, has invested £50m in Oxford Nanopore, in a deal that values the UK developer of gene-reading machines at £1.5bn. California-based Amgen is the first big user of DNA sequencing machines to invest in Nanopore. , which searches through human genomes for causes of disease that could lead to new drugs, is already an enthusiastic customer, according to its founder Kári Stefánsson.

  • Amgen Launches Humira Biosimilar in Europe
    GuruFocus.com6 days ago

    Amgen Launches Humira Biosimilar in Europe

    Amgen (AMGN) soared 3.45% to $202.34 per share on Oct. 16 following the commercial launch of Amgevita in Europe. Amgevita is a biosimilar of AbbVie's (ABBV) Humira and the trade name of adalimumab. The product is used as a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, chronic psoriasis and other conditions.

  • Reuters6 days ago

    Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
    Reuters6 days ago

    Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
    Investing.com6 days ago

    Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises

    Investing.com - Stocks in focus in pre-market trade Wednesday:

  • Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?
    Zacks6 days ago

    Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?

    Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.

  • The Wall Street Journal6 days ago

    [$$] By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S.

    Cheaper copies of the world’s biggest-selling drug will roll out across Europe this week after a key European patent for Humira expires Tuesday, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug. The reason: a formidable wall of patents built up by Humira-maker AbbVie Inc., that prevents the developers of “biosimilar” versions launching their products in the U.S. Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells in a process that resembles brewing.

  • Investing.com7 days ago

    Amgen Rises 3%

    Investing.com - Amgen (NASDAQ:AMGN) rose by 3.10% to trade at $201.66 by 14:31 (18:31 GMT) on Tuesday on the NASDAQ exchange.

  • How Nektar Therapeutics Is Positioned In October
    Market Realist7 days ago

    How Nektar Therapeutics Is Positioned In October

    Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.

  • 4 Strong Stocks to Buy That Double As Big Takeover Targets
    InvestorPlace7 days ago

    4 Strong Stocks to Buy That Double As Big Takeover Targets

    One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.

  • Benzinga7 days ago

    The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • Reuters7 days ago

    Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

    Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.